- Recent trends in the cell and gene therapy space
- How CAR-T therapies have been gaining momentum and what kind of progress we can expect in the next 10 years
- Personalized medicine and gene editing advances
- The biggest hurdles within cell and gene therapy space and how do we begin to jump over them
- Patient advocacy
- The biggest foci for cell and gene therapy for the next five years
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
- Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
- How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
- What needs to be done for GLP-1s to be covered
- Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
- Advice for investors and financiers who are considering entering the weight-loss medication market
Ian Baer, Founder and Chief Soothsayer, Sooth, discusses:
- His companies recent data and research about some massive behavioral shifts occurring across Gen-Z
- How pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation.
Jingsong Wang, Chairman of Nona Biosciences, discusses:
- Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.
